Development of a Blood Test for Colorectal Cancer based on Metabolomic Signature**

结直肠癌（CRC）是西方世界癌症死亡的第二大原因。**理想情况下，早期发现结直肠癌，因为在疾病晚期治疗变得越来越复杂，毒性和昂贵，并且在疾病早期生存率最高。这是筛选的基础。目前，筛查的金标准是结肠镜检查，这是一种侵入性的、昂贵的、难以在大量人群中进行的检查。一种策略是通过粪便测试（称为粪便免疫组化测试，FIT）来丰富需要结肠镜检查的亚群。问题是大便测试的依从性低于40%，因为大便测试是令人反感和不方便的。我们开发了一种基于血清化学成分的血液检测方法。这种测试非常敏感，已经在600多名患者身上进行了测试。在这个项目中，我们将与Med-Life**Discoveries and Innovate Calgary以及一个多学科科学团队合作，进一步完善该测试，然后创建一个可在典型临床实验室使用的诊断测试。**将开发软件以提高分析测试结果的能力。最后，我们将**对从近3500名**进行过结肠镜筛查的人**收集的血液样本进行**测试新的诊断测试。最后，我们将有一个方便的，临床适用的测试**，未来将在更大的临床试验中进行测试，这将告知监管机构**和临床医生这种新测试作为替代筛查工具的价值。

Colorectal cancer (CRC) is the second leading cause of cancer death in the western world.**Ideally, CRC will be detected early because treatments become progressively more**complicated, toxic and expensive in later disease stages, and the survival is best in early**stage of disease. That is the basis of screening. Currently, the gold standard screening test is**colonoscopy, which is invasive, expensive and difficult to perform on large populations. One**strategy is to enrich the subgroup that requires a colonoscopy by doing a stool test (called a**fecal immunohistochemical test, FIT). The problem is that compliance for stool tests is less**than 40% because testing stool is objectionable and inconvenient. We have developed a**blood test based on the chemical composition of serum. This test is quite sensitive and it has**already been tested on over 600 patients. In this project, in collaboration with Med-Life**Discoveries and Innovate Calgary, as well as a multidisciplinary science team, we will further**refine the test, then create a diagnostic test that can be used in a typical clinical laboratory.**Software will be developed to enhance the capability to analyze test results. Finally, we will**test the new diagnostic test on blood samples collected from close to 3500 individuals who**had screening colonoscopies. At the end, we will have a convenient, clinically applicable test**that will be tested in the future in a larger clinical trial that would inform regulatory agencies**and clinicians on the value of this new test as an alternative screening tool.